OncoTect Predictors
Precision starts here.
Our OncoTect technology leverages cancer biology, cutting-edge bioinformatics, machine learning, and clinical validation to guide treatment decisions.
OncoTect is a transformative leap toward data-driven precision oncology, where every patient receives the safest, most effective therapy tailored to their biology.
By analyzing a patient’s RNA expression profile from a routine biopsy, the platform predicts the likelihood of therapeutic success before treatment begins.
OncoTect simply works like this…
1. Analyze the Tumor’s RNA
By integrating RNA expression data from hundreds of genes with advanced bioinformatics, machine learning, and clinical insights, we can predict how a patient’s tumor will respond to specific cancer therapies.
2. Generate an AIDA Score
Each drug receives a score from 0 to 100, indicating the patient’s likelihood of responding to that treatment. A higher score reflects a greater chance of effectiveness.
3. Guide Treatment Decisions
These predictions help oncologists personalize treatment, selecting the therapies most likely to succeed - based on specific patient data, not just historical data from other patients.
See our range of OncoTect Predictors
EpiTect
Anthracycline Prediction
Anthracyclines like epirubicin and doxorubicin are widely used in breast cancer treatment, but response rates remain low while toxicity is high. EpiTect predicts individual response to these drugs, helping clinicians and patients choose the most effective treatment and avoid those unlikely to work.
TaxaTect
Taxane Prediction
Taxanes, such as docetaxel and paclitaxel, are a cornerstone of breast cancer treatment and are routinely used in both early-stage and advanced disease. However, not all patients benefit equally. TaxaTect predicts individual response to taxanes, helping clinicians tailor treatment, avoid unnecessary toxicity, and improve outcomes from the start.
Whats Next?
We are launching EpiTect in Denmark in 2026, starting with breast cancer. Next, we will expand to additional drugs and cancer types, building a comprehensive platform for personalized chemotherapy. We are also preparing for clinical guideline adoption, paving the way for future reimbursement and large scale impact.